Class
Article
College
College of Engineering
Department
Biological Engineering Department
Faculty Mentor
David Britt
Presentation Type
Poster Presentation
Abstract
Cytomegalovirus (CMV), a herpes class virus, is prevalent among the U.S. population. Congenital CMV infection is a leading cause of progressive hearing loss in children. Current treatments focus on ganciclovir, an engineered small-molecule drug. While ganciclovir treatments are the clinical gold standard, toxic side effects such as reduced blood cell counts can occur with prolonged treatment. In an effort to improve treatments, quercetin and Pluronic F68 nanoparticles (QF68) were screened as an excipient. Excipients are added to drug formulations to improve treatment properties; in this study QF68 and ganciclovir were coadministered.Two cell lines were investigated: (1) fibroblasts (connective tissue) and (2) stria vascularis epithelial cells (inner ear tissue). We observed that 1000-fold decreases in ganciclovir doses could be equally as effective when supplemented with QF68. Fluorescent microscopy verified cell uptake and mitochondrial partitioning of QF68 in both cell lines. Taken together, these data provide convincing evidence to transition to small animal models. Presentation Time: Thursday, 9-10 a.m. Zoom link: https://usu-edu.zoom.us/j/86532446768?pwd=M0prUXFFWUJPeTVPSS9BWEVsSWxFdz09
Location
Logan, UT
Start Date
4-12-2021 12:00 AM
Included in
Bioactive Excipients in Cytomegalovirus Treatment
Logan, UT
Cytomegalovirus (CMV), a herpes class virus, is prevalent among the U.S. population. Congenital CMV infection is a leading cause of progressive hearing loss in children. Current treatments focus on ganciclovir, an engineered small-molecule drug. While ganciclovir treatments are the clinical gold standard, toxic side effects such as reduced blood cell counts can occur with prolonged treatment. In an effort to improve treatments, quercetin and Pluronic F68 nanoparticles (QF68) were screened as an excipient. Excipients are added to drug formulations to improve treatment properties; in this study QF68 and ganciclovir were coadministered.Two cell lines were investigated: (1) fibroblasts (connective tissue) and (2) stria vascularis epithelial cells (inner ear tissue). We observed that 1000-fold decreases in ganciclovir doses could be equally as effective when supplemented with QF68. Fluorescent microscopy verified cell uptake and mitochondrial partitioning of QF68 in both cell lines. Taken together, these data provide convincing evidence to transition to small animal models. Presentation Time: Thursday, 9-10 a.m. Zoom link: https://usu-edu.zoom.us/j/86532446768?pwd=M0prUXFFWUJPeTVPSS9BWEVsSWxFdz09